Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
NRG Oncology
356 participants
Aug 21, 2025
INTERVENTIONAL
Conditions
Summary
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Undergo tumor tissue biopsy
Undergo blood sample collection
Given capecitabine
Undergo CT or PET/CT
Undergo dose-escalated radiation using intensity-modulated radiation therapy treatment planning
Given fluorouracil
Given gemcitabine
Given irinotecan hydrochloride
Given liposomal irinotecan
Given leucovorin calcium
Undergo MRI
Given nab-paclitaxel
Undergo observation
Given oxaliplatin
Undergo PET/CT
Ancillary studies
Undergo standard radiation therapy
Locations(279)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06958328